Research · Cohort study
Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on AMD progression: AREDS2 report 28
What it found
Lutein/zeaxanthin lowered progression to late AMD versus beta-carotene (HR 0.85) without its lung-cancer risk; omega-3 had no effect (HR 1.01).
- Design
- Cohort study
- Year
- 2022
- Sample size
- 3,882
- Population
- AREDS2 participants followed ~10 years
- Intervention
- lutein/zeaxanthin vs beta-carotene, and omega-3 vs none, within the AREDS formula
- Outcome
- progression to late AMD over 10 years
- Journal
- JAMA Ophthalmology
Citation last checked 2026-06-21.